CGREF1 Antibody

What is CGREF1 and what structural characteristics are important when selecting antibodies?

CGREF1 (Cell Growth Regulator with EF-hand Domain 1), also known as CGR11, is a 301 amino acid secreted protein containing two highly conserved calcium binding EF-hand domains that mediate cell-cell adhesion . The protein has a calculated molecular weight of 32 kDa, though it is sometimes observed at around 22 kDa in Western blots .

When selecting antibodies, researchers should consider:

• The specific domain targeted (N-terminal vs C-terminal antibodies are available)

• The presence of the signal peptide (important for secreted protein detection)

• The conservation of CGREF1 across species (human CGREF1 shares significant homology with mouse and rat orthologs)

CGREF1 was originally identified as a p53-inducible protein capable of inhibiting cell growth in various cell lines . Recent research has revealed its role as a CREB-H-regulated hepatokine involved in metabolism .

What are the principal applications of CGREF1 antibodies in laboratory research?

CGREF1 antibodies have been validated for multiple applications:

Researchers should perform antibody validation in their specific experimental system, as reactivity can vary between human, mouse, and rat samples . The optimal dilution should be determined empirically for each application and tissue type .

How is CGREF1 expressed across different tissues, and what methods are best for analyzing its expression pattern?

CGREF1 exhibits tissue-specific expression patterns:

• High expression: Brain, kidney, and liver (particularly in HCC tissues)

• Moderate expression: Heart, lung, and skeletal muscle

• Limited/no expression: Spleen and testis

For analyzing expression patterns, researchers can employ:

• RT-qPCR: Using validated primers targeting conserved regions (e.g., 5′-CAAAGGATGGAGTCACAAGGC-3′ and 5′-GAAGGGGTTGGGCAGGAG-3′ for human CGREF1)

• Immunohistochemistry: For tissue-specific localization, using dilutions of 1:50-1:200

• Western blotting: To compare protein levels across tissues (1:500-1:2000 dilution recommended)

• Bioinformatics analysis: Using databases like UALCAN and GEPIA to analyze mRNA expression patterns in normal vs. disease tissues

Recent research has shown upregulation of CGREF1 in hepatocellular carcinoma compared to normal liver tissues, correlating with poor patient prognosis .

What is the role of CGREF1 in hepatocellular carcinoma (HCC) progression and how can researchers study this function?

CGREF1 has been identified as a potential oncogene in HCC, with several key findings:

Researchers studying CGREF1's function in HCC should consider:

• Using genetic knockdown and overexpression models in HCC cell lines

• Implementing functional assays (MTT, colony formation, Transwell)

• Analyzing pathway activation through Western blotting

• Performing Gene Set Enrichment Analysis (GSEA) to identify associated pathways

• Validating findings with patient samples and survival data

How does CGREF1 function as a hepatokine in metabolic regulation, and what experimental approaches reveal its metabolic effects?

CGREF1 has recently been identified as a CREB-H-regulated hepatokine that modulates lipid metabolism . Key findings include:

• Regulation by CREB-H: CGREF1 expression is induced by the hepatic transcription factor CREB-H, as evidenced by downregulation in Creb3l3-/- mice .

• Target tissues: Secreted CGREF1 primarily targets epididymal white adipose tissue (eWAT), where it:

  • Suppresses insulin signaling

  • Inhibits glucose uptake

• Metabolic impact: Cgref1-/- mice show:

  • Lower tendencies to develop obesity

  • Reduced hyperglycemia

  • Improved dyslipidemia

  • Compromised hepatic function

• Diet responsiveness: CGREF1 expression is enhanced by high-fat diet (HFD) consumption, as shown by immunohistochemical staining of liver tissues .

Recommended experimental approaches for metabolic studies:

• Generate and characterize Cgref1-/- knockout mice

• Perform transcriptomic, metabolomic, and lipidomic analyses

• Conduct metabolic assays for glucose tolerance and insulin sensitivity

• Use gain-of-function and loss-of-function assays in primary hepatocytes

• Analyze expression in different nutritional states (fasting vs. fed)

• Examine expression in various metabolic disease models

What are the challenges in detecting endogenous CGREF1 protein, and what strategies can overcome these limitations?

Detecting endogenous CGREF1 presents several challenges:

• Variable molecular weight: While the calculated molecular weight is 32 kDa, CGREF1 is often observed at ~22 kDa in Western blots , suggesting potential post-translational modifications or alternative splicing.

• Dual localization: As a secreted protein with calcium-binding domains, CGREF1 may be present in both intracellular and extracellular compartments, requiring different extraction methods.

• Low expression levels: In some tissues, endogenous expression may be below detection thresholds of standard methods.

• Signal peptide cleavage: The presence of a signal peptide means the mature protein differs from the full-length version.

• Species differences: Human, mouse, and rat CGREF1 proteins have differences that may affect antibody recognition.

Strategies to overcome these limitations:

• Use multiple antibodies targeting different epitopes (N-terminal vs. C-terminal)

• Implement concentration methods for secreted proteins (e.g., TCA precipitation)

• Include positive controls with known CGREF1 expression (e.g., brain tissue)

• Optimize extraction buffers for calcium-binding proteins

• Consider immunoprecipitation before Western blotting to enrich for low-abundance CGREF1

• Validate antibody specificity using recombinant expression or knockout controls

What are the recommended protocols for using CGREF1 antibodies in Western blotting?

For optimal Western blot results with CGREF1 antibodies:

Sample preparation:

• For tissue samples: Homogenize in RIPA buffer with protease inhibitors

• For secreted CGREF1: Collect conditioned media and concentrate using TCA precipitation

• Include positive controls like brain or liver tissue

SDS-PAGE conditions:

• Use 10-12% polyacrylamide gels for optimal resolution around 22-32 kDa

• Load 20-50 μg of total protein per lane

Transfer and detection:

• Transfer to PVDF membranes at 100V for 1 hour or 30V overnight

• Block with 5% non-fat milk in TBST for 1 hour at room temperature

• Incubate with primary antibody at recommended dilution (typically 1:500-1:2000)

• Wash extensively with TBST (3-5 times, 5 minutes each)

• Incubate with HRP-conjugated secondary antibody

• Develop using ECL substrate and appropriate exposure times

Troubleshooting:

• If no signal is detected, try increasing antibody concentration or protein loading

• If multiple bands appear, optimize blocking conditions or antibody dilution

• For tissue-specific optimization, refer to literature using the same tissue type

How can researchers validate the specificity of CGREF1 antibodies in their experimental systems?

Validating antibody specificity is crucial for reliable research results. For CGREF1 antibodies:

• Genetic validation approaches:

  • Compare antibody signal in wild-type vs. CGREF1 knockout samples

  • Use siRNA or shRNA knockdown of CGREF1 to demonstrate signal reduction

  • Perform overexpression studies with tagged CGREF1 to confirm co-localization

• Biochemical validation approaches:

  • Pre-absorption test: Pre-incubate antibody with immunizing peptide

  • Use multiple antibodies targeting different epitopes

  • Compare with commercially available recombinant CGREF1 protein as positive control

• Technical validation:

  • Assess signal in tissues known to express (brain, kidney) or not express (spleen) CGREF1

  • Confirm expected molecular weight (approximately 22-32 kDa)

  • Perform immunoprecipitation followed by mass spectrometry

  • Use antibodies validated by enhanced validation methods, such as recombinant expression

• Controls to include:

  • Positive control: Tissues or cells with known CGREF1 expression

  • Negative control: Secondary antibody only

  • Isotype control: Non-specific IgG matching the host species of the primary antibody

What approaches should be used for immunohistochemical detection of CGREF1 in different tissue types?

For successful immunohistochemical detection of CGREF1:

Tissue preparation:

• Formalin fixation and paraffin embedding is suitable for most tissues

• Antigen retrieval is critical: Use citrate buffer (pH 6.0) or EDTA buffer (pH 9.0) with heat-induced retrieval

• Section thickness of 4-5 μm is recommended

Staining protocol:

• Deparaffinize and rehydrate sections

• Perform antigen retrieval

• Block endogenous peroxidase activity with 3% H₂O₂

• Block non-specific binding with serum matching the secondary antibody host

• Incubate with CGREF1 primary antibody at 1:50-1:200 dilution

• Apply appropriate detection system (ABC or polymer-based)

• Develop with DAB and counterstain with hematoxylin

Tissue-specific considerations:

• Liver tissue: Important for analyzing CGREF1 in metabolic studies and HCC research; compare normal vs. disease areas within the same section for internal control

• Brain tissue: Known to express high levels of CGREF1; useful as positive control

• Adipose tissue: Important for metabolic studies, may require modified fixation protocols

Controls:

• Include positive, negative, and isotype controls

• For HCC studies, include both tumoral and adjacent non-tumoral tissues

• For metabolic studies, compare normal diet vs. high-fat diet samples

How can researchers investigate the interaction between CGREF1 and the Wnt/β-Catenin signaling pathway?

Given CGREF1's role in activating the Wnt/β-Catenin pathway in HCC , researchers can:

• Analyze protein interaction and pathway activation:

  • Co-immunoprecipitation to detect interactions between CGREF1 and pathway components

  • Western blotting to measure p-β-Catenin and β-Catenin levels following CGREF1 manipulation

  • Immunofluorescence to examine β-Catenin nuclear translocation

  • TOP/FOP flash reporter assays to measure Wnt/β-Catenin transcriptional activity

• Pathway manipulation experiments:

  • Use CGREF1 overexpression and knockdown in cellular models

  • Employ Wnt pathway inhibitors (e.g., XAV939) to determine if they can reverse CGREF1-mediated effects

  • Perform rescue experiments with constitutively active β-Catenin in CGREF1-depleted cells

• Gene expression analysis:

  • RT-qPCR for Wnt target genes (e.g., cyclin D1, c-myc, MMP7)

  • RNA-seq to identify global changes in gene expression

  • ChIP assays to examine β-Catenin binding to target gene promoters

• Focus on EIF3H regulation:

  • As CGREF1 positively regulates EIF3H expression , analyze EIF3H levels in response to CGREF1 manipulation

  • Investigate if EIF3H knockdown can negate CGREF1-mediated Wnt activation

  • Perform promoter analyses to identify potential binding sites for transcription factors regulated by CGREF1

What are the most effective methods for studying CGREF1's role as a hepatokine in metabolic diseases?

To investigate CGREF1's function as a hepatokine in metabolic regulation:

• In vivo approaches:

  • Generate tissue-specific CGREF1 knockout mice using Cre-loxP system

  • Perform metabolic phenotyping (glucose/insulin tolerance tests, hyperinsulinemic-euglycemic clamps)

  • Challenge mice with different diets (normal vs. high-fat diet)

  • Analyze serum CGREF1 levels in different metabolic states and disease models

  • Conduct hepatokine secretion assays using primary hepatocytes

• Mechanistic studies:

  • Investigate CREB-H-mediated regulation of CGREF1 using ChIP assays

  • Analyze CGREF1 effects on specific signaling pathways in target tissues (especially eWAT)

  • Examine the impact on insulin signaling components (e.g., Akt phosphorylation)

  • Perform metabolomic and lipidomic analyses to identify affected metabolites

• Translational approaches:

  • Measure circulating CGREF1 levels in patients with metabolic disorders

  • Correlate CGREF1 levels with clinical parameters (BMI, glycemia, lipid profile)

  • Analyze CGREF1 expression in liver biopsies from patients with MASLD/NASH

  • Investigate potential genetic variants affecting CGREF1 expression or function

• Therapeutic targeting:

  • Develop neutralizing antibodies against CGREF1

  • Test the metabolic effects of CGREF1 inhibition in disease models

  • Investigate the regulation of CGREF1 by existing anti-diabetic drugs

What technical challenges exist in detecting secreted versus intracellular CGREF1, and how can they be addressed?

CGREF1 contains a signal peptide and functions as a secreted hepatokine , presenting unique detection challenges:

Challenges:

• The signal peptide is cleaved during secretion, resulting in different protein sizes

• Secreted proteins are often present at low concentrations in media or serum

• Different antibodies may preferentially detect either intracellular or secreted forms

• Post-translational modifications may differ between cellular and secreted forms

Solutions:

• For secreted CGREF1:

  • Concentrate conditioned media using TCA precipitation, ultrafiltration, or immunoprecipitation

  • Develop ELISA systems with high sensitivity (1:20000-1:40000 dilution range)

  • Use serum-free media for in vitro secretion studies to avoid interference

  • Consider signal peptide cleavage when selecting antibodies (avoid antibodies targeting only the signal peptide region)

• For intracellular CGREF1:

  • Use proper subcellular fractionation to distinguish ER/Golgi-associated from cytosolic protein

  • Select antibodies that recognize mature protein (post-signal peptide cleavage)

  • Include protease inhibitors during cell lysis to prevent degradation

  • Consider calcium chelators in buffers when studying EF-hand domain proteins

• Comparative analysis:

  • Use cell lines with tetracycline-inducible CGREF1 expression to control protein levels

  • Compare secreted versus cellular retention using wild-type and signal peptide mutants

  • Assess glycosylation status, which may differ between intracellular and secreted forms

How can researchers investigate the relationship between CGREF1's calcium-binding domains and its biological function?

CGREF1 contains two EF-hand domains responsible for calcium binding , which likely influence its function:

Experimental approaches:

• Structure-function analysis:

  • Generate EF-hand domain mutants with altered calcium-binding capacity

  • Compare wild-type and mutant protein for functional differences in cell proliferation, migration, and invasion assays

  • Perform circular dichroism spectroscopy to analyze conformational changes upon calcium binding

  • Use calcium-binding assays (e.g., 45Ca overlay) to confirm binding activity

• Calcium dependence studies:

  • Manipulate intracellular and extracellular calcium levels using chelators or ionophores

  • Examine CGREF1 localization and function under different calcium concentrations

  • Investigate calcium-dependent protein interactions using proximity ligation assays

  • Perform calcium imaging in cells expressing wild-type versus mutant CGREF1

• Bioinformatic approaches:

  • Compare CGREF1's EF-hand domains with other calcium-binding proteins

  • Model the structure of CGREF1's EF-hand domains based on homology to known structures

  • Identify potential calcium-dependent interaction partners based on structural predictions

• Physiological relevance:

  • Investigate if CGREF1's role in metabolism or cancer progression depends on calcium binding

  • Examine if calcium fluctuations alter CGREF1 secretion or activity

  • Assess if disease states with altered calcium homeostasis affect CGREF1 function

Understanding the calcium-binding properties of CGREF1 may provide insights into both its normal physiological function and its pathological roles in cancer and metabolic disorders.